ATE346613T1 - Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica - Google Patents

Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica

Info

Publication number: ATE346613T1
Authority: AT; Austria
Prior art keywords: inhibitors; insulin; glucose; fructose; nvp
Prior art date: 2000-01-21

Application number

AT01909661T

Other languages

English (en)

Inventor

Boerk Balkan

Thomas Edward Hughes

David Grenville Holmes

Edwin Bernard Villhauer

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-21

Filing date

2001-01-19

Publication date

2006-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27049636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE346613(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-19 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2006-12-15 Application granted granted Critical

2006-12-15 Publication of ATE346613T1 publication Critical patent/ATE346613T1/de

Links

229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title 1
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
208000002705 Glucose Intolerance Diseases 0.000 abstract 2
102000003638 Glucose-6-Phosphatase Human genes 0.000 abstract 2
108010086800 Glucose-6-Phosphatase Proteins 0.000 abstract 2
102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 2
108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 2
102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 abstract 2
101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 abstract 2
239000003623 enhancer Substances 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
201000009104 prediabetes syndrome Diseases 0.000 abstract 2
108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 2
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 abstract 2
VFFZWMWTUSXDCB-ZDUSSCGKSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VFFZWMWTUSXDCB-ZDUSSCGKSA-N 0.000 abstract 1
208000010444 Acidosis Diseases 0.000 abstract 1
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
102000027487 Fructose-Bisphosphatase Human genes 0.000 abstract 1
108010017464 Fructose-Bisphosphatase Proteins 0.000 abstract 1
229940122904 Glucagon receptor antagonist Drugs 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000007976 Ketosis Diseases 0.000 abstract 1
206010027417 Metabolic acidosis Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
239000000674 adrenergic antagonist Substances 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
230000030136 gastric emptying Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000009229 glucose formation Effects 0.000 abstract 1
230000002440 hepatic effect Effects 0.000 abstract 1
230000001771 impaired effect Effects 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
230000004140 ketosis Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229930029653 phosphoenolpyruvate Natural products 0.000 abstract 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1
150000003384 small molecules Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
229960001254 vildagliptin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT01909661T 2000-01-21 2001-01-19 Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica ATE346613T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48923400A	2000-01-21	2000-01-21
US61926200A	2000-07-19	2000-07-19

Publications (1)

Publication Number	Publication Date
ATE346613T1 true ATE346613T1 (de)	2006-12-15

Family

ID=27049636

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06121895T ATE385421T1 (de)	2000-01-21	2001-01-19	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
AT01909661T ATE346613T1 (de)	2000-01-21	2001-01-19	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT06121895T ATE385421T1 (de)	2000-01-21	2001-01-19	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica

Country Status (17)

Country	Link
US (1)	US20030139434A1 (de)
EP (5)	EP1741446B1 (de)
JP (7)	JP2003520226A (de)
CN (3)	CN1400908A (de)
AT (2)	ATE385421T1 (de)
AU (1)	AU2001237321A1 (de)
BR (1)	BRPI0107715B8 (de)
CA (2)	CA2673615C (de)
CY (6)	CY1106303T1 (de)
DE (3)	DE60132723T2 (de)
DK (5)	DK1743655T3 (de)
ES (5)	ES2436610T3 (de)
FR (1)	FR08C0017I2 (de)
LU (1)	LU91436I2 (de)
NL (1)	NL300346I1 (de)
PT (5)	PT1743655E (de)
WO (1)	WO2001052825A2 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2684168B2 (ja)	1995-10-30	1997-12-03	トーワ株式会社	離型抵抗力測定方法及び測定装置
WO1998039344A1 (en)	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Novel purine inhibitors of fructose-1,6-bisphosphatase
CZ297264B6 (cs)	1998-09-09	2006-10-11	Metabasis Therapeutics, Inc.	Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
IL141967A0 (en) *	1998-09-17	2002-03-10	Akesis Pharm Inc	Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
ATE385421T1 (de) *	2000-01-21	2008-02-15	Novartis Pharma Gmbh	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
EP1607401A1 (de)	2000-03-08	2005-12-21	Metabasis Therapeutics, Inc.	Neue Aryl-Fructose-1,6-Bisphosphatase-Inhibitoren
GB0014969D0 (en) *	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US7078397B2 (en)	2000-06-19	2006-07-18	Smithkline Beecham Corporation	Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CN101301294A (zh) *	2000-07-06	2008-11-12	症变治疗公司	Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
AU2002246855B2 (en) *	2000-10-23	2005-12-22	Smithkline Beecham Corporation	Novel compounds
JP3909056B2 (ja)	2001-06-27	2007-04-25	スミスクラインビーチャムコーポレーション	ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
ATE380175T1 (de)	2001-06-27	2007-12-15	Smithkline Beecham Corp	Pyrrolidine als dipeptidyl peptidase inhibitoren
ATE370943T1 (de)	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
ATE486842T1 (de)	2002-03-12	2010-11-15	Merck Sharp & Dohme	Substituierte amide
US7524885B2 (en) *	2002-04-01	2009-04-28	The Governors Of The University Of Alberta	Compounds that stimulate glucose utilization and methods of use
GB0212412D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
CN100402026C (zh) *	2002-06-03	2008-07-16	诺瓦提斯公司	取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2496249C (en) *	2002-08-21	2012-01-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
WO2004022083A1 (en) *	2002-09-04	2004-03-18	Dsm Ip Assets B.V.	A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
NZ538936A (en) *	2002-09-26	2006-12-22	Eisai Co Ltd	Combination drug comprising a combination of a dipeptidyl peptidase IV (DPPIV) inhibitor with biguanide
CN100348189C (zh) *	2002-12-10	2007-11-14	诺瓦提斯公司	DPP－IV抑制剂与PPAR－α化合物的组合
US20040242568A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
KR20060105431A (ko) *	2003-06-27	2006-10-11	닥터 레디스 리서치 파운데이션	발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물
FR2858556B1 (fr) *	2003-08-06	2006-03-10	Galenix Innovations	Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
MXPA06001601A (es)	2003-08-13	2006-08-25	Takeda Pharmaceutical	Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
AU2004267955A1 (en) *	2003-09-02	2005-03-10	Prosidion Ltd.	Combination therapy for glycaemic control
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US20070149451A1 (en) *	2003-11-17	2007-06-28	Holmes David G	Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
JP2007511487A (ja)	2003-11-17	2007-05-10	ノバルティスアクチエンゲゼルシャフト	ジペプチジルペプチダーゼｉｖ阻害剤の使用
JP5122144B2 (ja)	2004-01-20	2013-01-16	ノバルティスアーゲー	直接圧縮製剤および方法
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN102079743B (zh)	2004-03-15	2020-08-25	武田药品工业株式会社	二肽基肽酶抑制剂
JP2007261945A (ja) *	2004-04-07	2007-10-11	Taisho Pharmaceut Co Ltd	チアゾール誘導体
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) *	2004-05-28	2013-11-21	必治妥施貴寶公司	加衣錠片調製物及製備彼之方法
WO2005117861A1 (en) *	2004-06-04	2005-12-15	Novartis Ag	Use of organic compounds
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
EP1794120B1 (de)	2004-07-23	2012-04-11	Nuada, LLC	Peptidaseinhibitoren
EP1782832A4 (de) *	2004-08-26	2009-08-26	Takeda Pharmaceutical	Mittel zur behandlung von diabetes
EP1807066A1 (de) *	2004-10-25	2007-07-18	Novartis AG	Kombination aus dpp-iv-hemmer, ppar-antidiabetikum und metformin
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008524331A (ja)	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
CN101332303B (zh) *	2005-01-10	2012-09-26	艾尼纳制药公司	用于治疗糖尿病和其相关病状以及用于治疗通过增加血液glp-1水平而改善的病状的组合疗法
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
AU2006229995A1 (en) *	2005-03-25	2006-10-05	Glaxo Group Limited	Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
MY145281A (en) *	2005-03-25	2012-01-13	Glaxo Group Ltd	Novel compounds
MX2007011453A (es)	2005-04-22	2008-02-12	Alantos Pharmaceuticals Holding Inc	Inhibidores de la dipeptidil peptidasa-iv.
JP2008115080A (ja) *	2005-04-22	2008-05-22	Taisho Pharmaceutical Co Ltd	併用医薬
BRPI0611074A2 (pt)	2005-06-03	2010-11-23	Mitsubishi Tanabe Pharma Corp	agentes farmacêuticos concomitantes e uso dos mesmos
MY152185A (en) *	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
JP2009500401A (ja) *	2005-07-07	2009-01-08	ポステックファンデーション	糖吸収調節剤及び薬学的組成物
KR20080028422A (ko) *	2005-07-12	2008-03-31	노파르티스 아게	Ｄｐｐ-ｉｖ 억제제 및 칸나비노이드 ｃｂ1 수용체길항제의 배합물
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ566799A (en)	2005-09-14	2011-04-29	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (en)	2005-09-16	2007-03-29	Takeda Pharmaceutical Company Limited	Process for the preparation of pyrimidinedione derivatives
AU2006292377B2 (en) *	2005-09-20	2011-03-03	Emisphere Technologies, Inc.	Use of a DPP-IV inhibitor to reduce hypoglycemic events
TW200738266A (en) *	2005-09-29	2007-10-16	Sankyo Co	Pharmaceutical agent containing insulin resistance improving agent
US20080227825A1 (en) *	2005-09-29	2008-09-18	Yatindra Joshi	Formulation
EP1940388A2 (de) *	2005-09-30	2008-07-09	Novartis AG	Dpp iv-hemmer zur verwendung bei der behandlung von autoimmunkrankheiten und transplantatabstossung
EP1951286A4 (de) *	2005-10-07	2009-11-04	Waratah Pharmaceuticals Inc	Kombinierte verwendung von dpp-iv-hemmern und gastrin-verbindungen
WO2007078726A2 (en) *	2005-12-16	2007-07-12	Merck & Co., Inc.	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
KR20080081354A (ko) *	2005-12-28	2008-09-09	다케다 야쿠힌 고교 가부시키가이샤	당뇨병 치료제
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
NZ571110A (en)	2006-04-11	2011-03-31	Arena Pharm Inc	Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual
BRPI0711558A2 (pt)	2006-05-04	2011-11-08	Boeringer Ingelheim Internat Gmbh	polimorfos
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
PL2073810T3 (pl) *	2006-09-13	2012-01-31	Takeda Pharmaceuticals Co	Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV
JP2010043002A (ja) *	2006-11-27	2010-02-25	Ajinomoto Co Inc	糖尿病治療剤
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TW201350143A (zh)	2007-02-01	2013-12-16	Takeda Pharmaceutical	固體型製劑
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
PE20090938A1 (es)	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CL2008003653A1 (es) *	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (de)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
KR101607081B1 (ko)	2008-05-14	2016-03-29	가부시키가이샤산와카가쿠켄큐쇼	디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
AU2009290911A1 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
AR074797A1 (es) *	2008-10-10	2011-02-16	Japan Tobacco Inc	Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2367554A4 (de)	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Gallensäurerückflusshemmer zur behandlung von adipositas und diabetes
US8318663B2 (en) *	2008-11-26	2012-11-27	Satiogen Pharmaceuticals, Inc.	Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
WO2010071750A1 (en) *	2008-12-19	2010-06-24	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds
EP2382216A1 (de)	2008-12-23	2011-11-02	Boehringer Ingelheim International GmbH	Salzformen einer organischen verbindung
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MX339194B (es)	2009-02-13	2016-05-16	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2525790B1 (de)	2009-10-21	2020-05-27	Agios Pharmaceuticals, Inc.	Verfahren und zusammensetzungen für zellproliferationsbedingte erkrankungen
WO2011050210A1 (en)	2009-10-21	2011-04-28	Agios Pharmaceuticals, Inc.	Methods and compositions for cell-proliferation-related disorders
EA034869B1 (ru)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
WO2011080276A1 (en)	2009-12-29	2011-07-07	Genfit	Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
JP2013523819A (ja)	2010-04-06	2013-06-17	アリーナファーマシューティカルズ，インコーポレイテッド	Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
MX341025B (es)	2010-05-05	2016-08-04	Boehringer Ingelheim Int Gmbh *	Terapia de combinacion.
EP4137137A1 (de)	2010-05-26	2023-02-22	Satiogen Pharmaceuticals, Inc.	Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
PH12012502524A1 (en)	2010-06-24	2014-02-10	Boehringer Ingelheim Int	Diabetes therapy
CN103221410B (zh)	2010-09-22	2017-09-15	艾尼纳制药公司	Gpr119受体调节剂和对与其相关的障碍的治疗
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3517539B1 (de)	2011-07-15	2022-12-14	Boehringer Ingelheim International GmbH	Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA038594B1 (ru)	2011-10-28	2021-09-21	Шайр Хьюман Дженетик Терапис, Инк.	Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja)	2011-10-28	2017-10-25	ルメナファーマシューティカルズエルエルシー	小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EA021236B1 (ru) *	2012-10-03	2015-05-29	Дафот Энтерпраизес Лимитед	Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
CN107683135A (zh)	2015-03-09	2018-02-09	因特克林医疗有限公司	用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
WO2018162722A1 (en)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Dpp-4 inhibitors for use in treating bone fractures
AU2018249822A1 (en)	2017-04-03	2019-10-31	Coherus Biosciences Inc.	PPArgamma agonist for treatment of progressive supranuclear palsy
JP2022548214A (ja)	2019-09-17	2022-11-17	ノバルティスアーゲー	ビルダグリプチンとメトホルミンとの組み合わせ療法
US20240369557A1 (en) *	2024-06-12	2024-11-07	Firoz Anwar	A blood profile analysis method for identification of new diabetes diagnostic markers in sars-cov-2 infected patients

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US489795A (en)		1893-01-10		Steadying device for portable engines
US988496A (en)	1910-09-19	1911-04-04	Henry Obermann	Ventilator.
US4062950A (en) *	1973-09-22	1977-12-13	Bayer Aktiengesellschaft	Amino sugar derivatives
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
US4342771A (en) *	1981-01-02	1982-08-03	Pfizer Inc.	Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
DE3347565A1 (de)	1983-12-30	1985-07-11	Thomae Gmbh Dr K	Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5216167A (en) *	1983-12-30	1993-06-01	Dr. Karl Thomae Gmbh	Phenylacetic acid benzylamides
AR240698A1 (es)	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPS6354321A (ja)	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
WO1986007056A1 (en)	1985-05-21	1986-12-04	Pfizer Inc.	Hypoglycemic thiazolidinediones
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5071773A (en)	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
ATE186724T1 (de)	1987-09-04	1999-12-15	Beecham Group Plc	Substituierte thiazolidindionderivate
US4981784A (en)	1987-12-02	1991-01-01	The Salk Institute For Biological Studies	Retinoic acid receptor method
WO1989008651A1 (en)	1988-03-08	1989-09-21	Pfizer Inc.	Hypoglycemic thiazolidinedione derivatives
EP0497894A4 (en)	1989-10-25	1993-03-31	The Salk Institute For Biological Studies	Receptor infection assay
US4997948A (en)	1989-10-27	1991-03-05	American Home Products	5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
EP0441483A3 (en)	1990-01-16	1992-11-19	Baylor College Of Medicine	Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
ES2113879T3 (es)	1990-01-24	1998-05-16	Douglas I Buckley	Analogos de glp-1 utiles para el tratamiento de diabetes.
JPH06503642A (ja)	1990-09-21	1994-04-21	ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ	プロトオンコタンパク質ｃ−ＪＵＮとホルモン受容体との間の機能的拮抗作用
DE69217762T2 (de)	1991-07-30	1997-10-09	Ajinomoto Kk	Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5866563A (en) *	1991-09-30	1999-02-02	The University Of British Columbia	Vanadium compositions
WO1993011235A1 (en)	1991-12-06	1993-06-10	The Salk Institute For Biological Studies	Multimeric forms of members of the steroid/thyroid superfamily of receptors
DE617614T1 (de)	1991-12-18	1995-06-08	Baylor College Of Medicine, Houston, Tex.	Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.
DE69333894D1 (de)	1992-04-22	2005-12-01	Ligand Pharm Inc	Verbindungen mit Retinoid x rezeptorselektivität
JPH07509694A (ja)	1992-05-14	1995-10-26	ベイラー・カレッジ・オブ・メディシン	突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5466861A (en)	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
JP2845743B2 (ja)	1992-12-28	1999-01-13	三菱化学株式会社	新規なナフタレン誘導体
CA2153235C (en)	1993-01-11	2005-08-23	Marcus F. Boehm	Compounds having selectivity for retinoid x receptors
WO1994015901A1 (en)	1993-01-11	1994-07-21	Ligand Pharmaceuticals Inc.	Compounds having selectivity for retinoid x receptors
ES2129115T3 (es)	1993-01-11	1999-06-01	Ligand Pharm Inc	Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
US5399586A (en)	1993-03-11	1995-03-21	Allergan, Inc.	Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
EP0694078A4 (de)	1993-04-07	1997-06-25	Ligand Pharm Inc	Screening-verfahren für rezeptoragonisten
US5506102A (en)	1993-10-28	1996-04-09	Ligand Pharmaceuticals Incorporated	Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
EP0737314A4 (de)	1993-12-30	1999-11-03	Salk Inst For Biological Studi	Verwendungen für gal 4-rezeptor-konstrukte
US5705515A (en)	1994-04-26	1998-01-06	Merck & Co., Inc.	Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
DE4416433A1 (de)	1994-05-10	1995-11-16	Hoechst Ag	Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
US5488510A (en)	1994-07-26	1996-01-30	Lemay; Edward J.	Enhanced depth perception viewing device for television
KR100363545B1 (ko)	1994-08-10	2003-02-19	에프. 호프만-라 로슈 아게	레틴산x-수용체리간드
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE187157T1 (de)	1994-12-30	1999-12-15	Ligand Pharm Inc	Trizyclische retinoidverbindungen verfahren zu ihrer herstellung und verwendung
MX9704878A (es)	1994-12-30	1997-11-29	Ligand Pharm Inc	Nuevos compuestos retinoides trienoicos y metodos de uso.
MX9709875A (es)	1995-06-06	1998-03-31	Pfizer	N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.
US6297269B1 (en)	1995-06-06	2001-10-02	Pfizer Inc.	Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
WO1997016442A1 (en)	1995-10-31	1997-05-09	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AU2090897A (en)	1996-02-29	1997-09-16	Mikael Bols	Hydroxyhexahydropyridazines
US5770615A (en)	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
EP1019043A4 (de)	1996-05-07	2003-07-30	Univ Pennsylvania	Inhibitoren der glykogensynthese-kinase 3 und verfahren zu ihrer identifizierung und verwendung
JP2000511903A (ja)	1996-06-07	2000-09-12	メルクエンドカンパニーインコーポレーテッド	糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
EP0827746B1 (de)	1996-09-05	2002-04-03	Eli Lilly And Company	Carbazolanaloge als selektive beta3-adrenergische Agonisten
JP4010377B2 (ja)	1996-09-06	2007-11-21	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5776954A (en)	1996-10-30	1998-07-07	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
FR2755439B1 (fr)	1996-11-05	1998-12-24	Virbac Sa	Derives aryloxypropanolamines, leur procede de preparation et leurs applications
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US5880139A (en)	1996-11-20	1999-03-09	Merck & Co., Inc.	Triaryl substituted imidazoles as glucagon antagonists
CA2271893A1 (en)	1996-11-20	1998-05-28	Linda L. Chang	Triaryl substituted imidazoles as glucagon antagonists
WO1998021957A1 (en)	1996-11-20	1998-05-28	Merck & Co., Inc.	Triaryl substituted imidazoles, compositions containing such compounds and methods of use
EP0959885A4 (de)	1996-11-20	2002-07-17	Merck & Co Inc	Triaryl substituierte imidazole und verfahren zur verwendung
US5952322A (en)	1996-12-05	1999-09-14	Pfizer Inc.	Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
IL131130A0 (en)	1997-01-28	2001-01-28	Merck & Co Inc	Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
EP0973778A1 (de)	1997-03-07	2000-01-26	Novo Nordisk A/S	4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-derivate ihre herstellung und ihre verwendung
DE69819311T2 (de)	1997-03-07	2004-07-29	Metabasis Therapeutics Inc., San Diego	Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
AU6691798A (en)	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en)	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1999001423A1 (en)	1997-07-01	1999-01-14	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
GB9715298D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
US6169087B1 (en)	1997-09-23	2001-01-02	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (PTPases)
UA57811C2 (uk)	1997-11-21	2003-07-15	Пфайзер Продактс Інк.	Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
WO1999029672A1 (en)	1997-12-05	1999-06-17	Eli Lilly And Company	SELECTIVE β3 ADRENERGIC AGONISTS
EP1052994A2 (de) *	1998-02-02	2000-11-22	Trustees Of Tufts College	Verwendung von dipetidylpeptidasehemmer zur regulierung des glukosemetabolismus
WO1999040062A1 (en)	1998-02-05	1999-08-12	Novo Nordisk A/S	Hydrazone derivatives
US5998463A (en)	1998-02-27	1999-12-07	Pfizer Inc	Glycogen phosphorylase inhibitors
WO1999046236A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
JP2002506073A (ja)	1998-03-12	2002-02-26	ノボノルディスクアクティーゼルスカブ	プロテイン・チロシン・ホスファターゼ（ＰＴＰａｓｅｓ）のモジュレーター
WO1999046267A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
WO1999046244A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
JP2004500308A (ja)	1998-03-12	2004-01-08	ノボ　ノルディスク　アクティーゼルスカブ	プロテインチロシンホスアターゼのモジュレーター
EP1070084A4 (de)	1998-03-16	2001-09-12	Ontogen Corp	Piperazine als inhibitoren der fruktose-1,6-bisphosphatase (fbpase)
CN1208326C (zh)	1998-04-23	2005-06-29	雷迪实验室有限公司	杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
US6331633B1 (en)	1998-05-08	2001-12-18	Calyx Therapeutics Inc.	Heterocyclic analogs of diphenylethylene compounds
EP1077968A1 (de)	1998-05-12	2001-02-28	American Home Products Corporation	Naphto[2,3-b]heteroar-4-yl-derivate
US6001867A (en)	1998-05-12	1999-12-14	American Home Products Corporation	1-aryl-dibenzothiophenes
WO1999058518A2 (en)	1998-05-12	1999-11-18	American Home Products Corporation	Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6057316A (en)	1998-05-12	2000-05-02	American Home Products Corporation	4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
EP0978279A1 (de)	1998-08-07	2000-02-09	Pfizer Products Inc.	Glycogen-phosphorylase inhibitoren
AU5154699A (en)	1998-09-02	2000-03-27	Novo Nordisk A/S	4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives
CZ297264B6 (cs)	1998-09-09	2006-10-11	Metabasis Therapeutics, Inc.	Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
JP2002527419A (ja)	1998-10-08	2002-08-27	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
CO5150173A1 (es) *	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB2351081A (en)	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Pharmaceutically active imidazoline compounds and analogues thereof
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6030837A (en)	1999-08-03	2000-02-29	Isis Pharmaceuticals Inc.	Antisense inhibition of PEPCK-mitochondrial expression
ATE385421T1 (de) *	2000-01-21	2008-02-15	Novartis Pharma Gmbh	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
TW200303742A (en) †	2001-11-21	2003-09-16	Novartis Ag	Organic compounds

2001
- 2001-01-19 AT AT06121895T patent/ATE385421T1/de active
- 2001-01-19 DK DK06121898.8T patent/DK1743655T3/da active
- 2001-01-19 ES ES06121896.2T patent/ES2436610T3/es not_active Expired - Lifetime
- 2001-01-19 US US10/181,169 patent/US20030139434A1/en not_active Abandoned
- 2001-01-19 ES ES06121894T patent/ES2433476T3/es not_active Expired - Lifetime
- 2001-01-19 PT PT61218988T patent/PT1743655E/pt unknown
- 2001-01-19 CN CN01803953A patent/CN1400908A/zh active Pending
- 2001-01-19 AU AU2001237321A patent/AU2001237321A1/en not_active Abandoned
- 2001-01-19 ES ES01909661T patent/ES2275654T5/es not_active Expired - Lifetime
- 2001-01-19 DK DK06121896.2T patent/DK1741447T3/da active
- 2001-01-19 CA CA2673615A patent/CA2673615C/en not_active Expired - Lifetime
- 2001-01-19 PT PT06121895T patent/PT1741446E/pt unknown
- 2001-01-19 DK DK01909661.9T patent/DK1248604T4/da active
- 2001-01-19 CN CN2011102233943A patent/CN102327614A/zh active Pending
- 2001-01-19 AT AT01909661T patent/ATE346613T1/de active
- 2001-01-19 EP EP06121895A patent/EP1741446B1/de not_active Expired - Lifetime
- 2001-01-19 ES ES06121895T patent/ES2301142T3/es not_active Expired - Lifetime
- 2001-01-19 DE DE60132723T patent/DE60132723T2/de not_active Expired - Lifetime
- 2001-01-19 BR BRPI0107715A patent/BRPI0107715B8/pt not_active IP Right Cessation
- 2001-01-19 EP EP06121898.8A patent/EP1743655B1/de not_active Expired - Lifetime
- 2001-01-19 DE DE60124861T patent/DE60124861T2/de not_active Expired - Lifetime
- 2001-01-19 CN CNA2006101699199A patent/CN1977842A/zh active Pending
- 2001-01-19 WO PCT/EP2001/000590 patent/WO2001052825A2/en not_active Ceased
- 2001-01-19 EP EP06121894.7A patent/EP1741445B1/de not_active Expired - Lifetime
- 2001-01-19 PT PT61218962T patent/PT1741447E/pt unknown
- 2001-01-19 PT PT61218947T patent/PT1741445E/pt unknown
- 2001-01-19 JP JP2001552873A patent/JP2003520226A/ja active Pending
- 2001-01-19 EP EP01909661A patent/EP1248604B2/de not_active Expired - Lifetime
- 2001-01-19 CA CA002397554A patent/CA2397554C/en not_active Expired - Lifetime
- 2001-01-19 DK DK06121895T patent/DK1741446T3/da active
- 2001-01-19 DE DE122008000018C patent/DE122008000018I1/de active Pending
- 2001-01-19 EP EP06121896.2A patent/EP1741447B1/de not_active Expired - Lifetime
- 2001-01-19 ES ES06121898.8T patent/ES2487897T3/es not_active Expired - Lifetime
- 2001-01-19 DK DK06121894.7T patent/DK1741445T3/da active
- 2001-01-19 PT PT01909661T patent/PT1248604E/pt unknown
2006
- 2006-07-10 JP JP2006189416A patent/JP2006273873A/ja active Pending
- 2006-12-29 CY CY20061101859T patent/CY1106303T1/el unknown
2008
- 2008-04-24 CY CY20081100459T patent/CY1107423T1/el unknown
- 2008-05-09 LU LU91436C patent/LU91436I2/fr unknown
- 2008-05-12 CY CY200800010C patent/CY2008010I2/el unknown
- 2008-05-14 FR FR08C0017C patent/FR08C0017I2/fr active Active
- 2008-05-14 NL NL300346C patent/NL300346I1/nl unknown
2011
- 2011-03-02 JP JP2011045331A patent/JP5835910B2/ja not_active Expired - Lifetime
- 2011-03-30 JP JP2011076253A patent/JP5824224B2/ja not_active Expired - Lifetime
2013
- 2013-10-09 CY CY20131100877T patent/CY1114466T1/el unknown
- 2013-11-08 CY CY20131100996T patent/CY1114593T1/el unknown
2014
- 2014-02-06 JP JP2014020963A patent/JP6095589B2/ja not_active Expired - Lifetime
- 2014-08-08 CY CY20141100633T patent/CY1115449T1/el unknown
2015
- 2015-07-31 JP JP2015151372A patent/JP6104331B2/ja not_active Expired - Lifetime
2017
- 2017-01-19 JP JP2017007638A patent/JP6374995B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK1743655T3 (da)	2014-08-18
PT1741446E (pt)	2008-05-09
EP1741445A3 (de)	2007-01-24
EP1741446A2 (de)	2007-01-10
CY2008010I1 (el)	2009-11-04
DE122008000018I1 (de)	2008-08-14
US20030139434A1 (en)	2003-07-24
DE60132723T2 (de)	2009-01-29
WO2001052825A3 (en)	2002-03-28
CY1107423T1 (el)	2010-07-28
JP2003520226A (ja)	2003-07-02
EP1741446A3 (de)	2007-01-17
ES2433476T3 (es)	2013-12-11
CN1977842A (zh)	2007-06-13
EP1248604B2 (de)	2012-02-29
ES2275654T3 (es)	2007-06-16
JP6374995B2 (ja)	2018-08-15
DE60124861D1 (de)	2007-01-11
HK1102424A1 (en)	2007-11-23
CA2673615C (en)	2013-07-16
EP1741447A2 (de)	2007-01-10
CY1114593T1 (el)	2016-10-05
JP2014088435A (ja)	2014-05-15
EP1741447B1 (de)	2013-09-18
JP5824224B2 (ja)	2015-11-25
DK1248604T3 (da)	2007-02-19
HK1108359A1 (en)	2008-05-09
EP1741445A2 (de)	2007-01-10
JP6104331B2 (ja)	2017-03-29
NL300346I1 (de)	2008-07-01
CY1115449T1 (el)	2017-01-04
FR08C0017I2 (fr)	2010-12-31
DE60132723D1 (de)	2008-03-20
CY2008010I2 (el)	2009-11-04
DK1741445T3 (da)	2013-11-04
PT1743655E (pt)	2014-09-09
JP2017081994A (ja)	2017-05-18
ES2301142T3 (es)	2008-06-16
FR08C0017I1 (de)	2008-07-18
JP2011116772A (ja)	2011-06-16
LU91436I2 (fr)	2008-07-09
BRPI0107715B1 (pt)	2016-07-05
EP1248604B1 (de)	2006-11-29
BR0107715A (pt)	2002-11-19
HK1102422A1 (en)	2007-11-23
PT1741447E (pt)	2013-12-11
BRPI0107715B8 (pt)	2021-05-25
HK1102405A1 (en)	2007-11-23
ES2436610T3 (es)	2014-01-03
DE60124861T2 (de)	2007-05-10
PT1741445E (pt)	2013-11-11
DK1741447T3 (da)	2013-12-09
JP5835910B2 (ja)	2015-12-24
WO2001052825A2 (en)	2001-07-26
JP6095589B2 (ja)	2017-03-15
ES2275654T5 (es)	2012-06-07
CA2397554C (en)	2009-09-22
PT1248604E (pt)	2007-01-31
DK1741446T3 (da)	2008-06-02
AU2001237321A1 (en)	2001-07-31
CN102327614A (zh)	2012-01-25
JP2011162550A (ja)	2011-08-25
CY1114466T1 (el)	2016-10-05
EP1741446B1 (de)	2008-02-06
CA2673615A1 (en)	2001-07-26
JP2015214572A (ja)	2015-12-03
CN1400908A (zh)	2003-03-05
CY1106303T1 (el)	2011-10-12
ES2487897T3 (es)	2014-08-25
CA2397554A1 (en)	2001-07-26
EP1743655B1 (de)	2014-06-25
EP1741445B1 (de)	2013-08-14
EP1248604A2 (de)	2002-10-16
DK1248604T4 (da)	2012-05-21
EP1741447A3 (de)	2007-01-17
ATE385421T1 (de)	2008-02-15
LU91436I9 (de)	2019-01-02
JP2006273873A (ja)	2006-10-12
EP1743655A1 (de)	2007-01-17

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1248604

Country of ref document: EP

Publication	Publication Date	Title
ATE385421T1 (de)	2008-02-15	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
WO2006070195A8 (en)	2006-08-24	Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
CA2432799A1 (en)	2002-06-27	Pyrazole compounds useful as protein kinase inhibitors
GB0220581D0 (en)	2002-10-09	Organic Compound
EP1423370A4 (de)	2007-04-18	An den nukleären fxr-nr1h4-rezeptor bindende verbindungen
IL153995A0 (en)	2003-07-31	2-aminopyridine derivatives and pharmaceutical compositions containing the same
CA2375259A1 (en)	2000-12-28	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
BR0212477A (pt)	2004-08-24	7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
BRPI0518409A2 (pt)	2008-11-18	combinaÇço de inibidor dpp-iv, antidiabÉtico ppar e metformina
EP1137413A4 (de)	2002-06-26	Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
AU2003229548A1 (en)	2003-09-09	Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis
TW200606961A (en)	2006-02-16	Ceramic electronic parts and method for manufacturing ceramic electronic parts
WO2006084757A3 (en)	2006-11-23	Combination of ca/mg salt of valsartan with an antidiabetic agent
FR2653113B1 (fr)	1994-03-04	Compositions verrieres oxyazotees, leurs precurseurs et leur application a la preparation de compositions vitroceramiques et de materiaux composites.
Liebmann et al.	1992	Binding characteristics and functional G protein coupling of muscarinic acetylcholine receptors in rat duodenum smooth muscle membranes